Evidence map›Paper›PMID 36382190›Full record

ReviewComputational and structural biotechnology journal2022

Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.

Xinyi Fang, Runyu Miao, Jiahua Wei, Haoran Wu, Jiaxing Tian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Impacts ofFood science & nutrition · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinyi FangInstitute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Runyu MiaoInstitute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Jiahua WeiChangchun University of Chinese Medicine, Jilin 130117, China.
Haoran WuGraduate College, Beijing University of Chinese Medicine, Beijing 100029, China.
Jiaxing TianInstitute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycolipid metabolism disorder are major threats to human health and life. Genetic, environmental, psychological, cellular, and molecular factors contribute to their pathogenesis. Several studies demonstrated that neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis are core pathological links associated with it. However, the underlying molecular mechanisms and therapeutic targets of glycolipid metabolism disorder remain to be elucidated. Progress in high-throughput technologies has helped clarify the pathophysiology of glycolipid metabolism disorder. In the present review, we explored the ways and means by which genomics, transcriptomics, proteomics, metabolomics, and gut microbiomics could help identify novel candidate biomarkers for the clinical management of glycolipid metabolism disorder. We also discuss the limitations and recommended future research directions of multi-omics studies on these diseases.

Indexed as

1,5-AG, 1,5-anhydroglucitol2-AAA, 2-aminoadipic acid2-DGE, two-dimensional gel electrophoresisABCC8, ATP binding cassette subfamily C member 8ADA, American Diabetes AssociationAhR, aromatic hydrocarbon receptorBA, bile acidBCAA, branched-chain amino acidBCKAs, branched chain keto acidsBiomarkersCE, cholesterol esterCFL1, cofilin-1circRNA, circular RNACRP, C reactive proteinCYP450, cytochrome P450DAG, diacylglycerolDPP-4, dipeptyl peptidase 4EASD, European Association for the Study of DiabetesFA, fatty acidFFA, free fatty acidFMT, fecal microbiota transplantationFTO, fat mass and obesity-associatedGAS5, growth arrest-specific transcript 5GC–MS/MS, gas chromatography-tandem mass spectrometryGLP-1, glucagon-like peptide 1GLP-1R, glucagon-like peptide 1 receptorGlycolipid metabolism disorderGSIS, glucose-stimulated insulin secretionGWAS, genome-wide association studyhADCS, human adipose-derived stem cellsHbA1C, glycylated hemoglobinHGF, hepatocyte growth factorHMG-CoA, hydroxymethylglutaryl-coenzyme AHMGCR, 3-hydroxy-methylglutaryl coenzyme A reductaseHPLC, high performance liquid chromatographyhsCRP, high-sensitivity C-reactive proteinIL-1ra, interleukin-1 receptor antagonistIMP, imidazole propionateIR, insulin resistanceJNK, c-Jun-N-terminal-kinaseKCNJ11, potassium inwardly rectifying channel subfamily J member 11LC-MS/MS, liquid chromatography-tandem mass spectrometryL-GPC, linoleoyl-glycerophosphocholinelnc-BATE1, brown adipose tissue enriched long non-coding RNA 1lncRNA, long non-coding RNAlncRNA SHGL, lncRNA suppressor of hepatic gluconeogenesis and lipogenesisLPC, lysophosphatidylcholineLPE, lysophosphatidylethanolaminesLPS, lipopolysaccharideMAPK, mitogen-activated protein kinaseMASP, mannose-binding lectin-associated serine protease 1MATE1, multidrug and toxin extrusion protein 1MDR1, multidrug resistance mutation 1Mechanism studyMGT, magnesium transportermiRNA, micro RNAmRNA, messenger RNAsMS, Mass SpectrometrymTORC1, mechanistic target of rapamycin complex 1Multi-omicsncRNA, non-coding RNANK, natural killerNMR, nuclear magnetic resonanceOCT, organic cationic transporterOGTT, oral glucose tolerance testPC-PL, phosphatidylcholine-plasmalogenPE, phosphatidylethanolaminesPNPLA3, patatin-like phospholipase domain-containing protein 3PPAR, peroxisome proliferator-activated receptorPTBP1, polypyrimidine tract-binding protein 1PTP, protein tyrosine phosphataseRNS, reactive nitrogen speciesROS, reactive oxygen speciesSCFA, short-chain fatty acidSLC30A8, solute carrier family 30 member 8SLC47A1, solute carrier family 47 member 1SLC5A2, solute carrier family 5 member 2SM, sphingomyelinSNP, single-nucleotide polymorphismSSPG, steady-state plasma glucoseSUR1, sulfonylurea receptor 1T2DM, type 2 diabetes mellitusTAG, triacylglycerolTCA, tricarboxylic acidTCF7L2, transcription factor 7-like 2TF, transcription factorTMAO, trimethylamine oxideTMA, trimethylamineTNF-α, tumor necrosis factor alphaTOF-MS, time-of-flight mass spectrumt-PA, tissue plasminogen activatorTUG1, taurine upregulated gene 1USP20, ubiquitin-specificpeptidase 20WBC, white blood cellα-HB, α-hydroxybutyrate

Identifiers

PMID36382190
PMCPMC9646750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.